Clinical Trials Directory

Trials / Completed

CompletedNCT01906944

Ultrasound Guided Transversus Abdominis Plane (TAP) vs. Trigger Point Injection (TPI) for Abdominal Wall Pain

Ultrasound Guided Transversus Abdominis Plane Block vs. Trigger Point Injection for Abdominal Wall Pain: A Randomized Comparative Trial

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
62 (actual)
Sponsor
Mayo Clinic · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Patients with chronic abdominal pain- with a component of abdominal wall pain- are often treated with trigger point injections. This study will help to determine if a block within the transversus abdominis plane (TAP) will provide superior analgesic benefit to a trigger point injection as therapy for these patients.

Detailed description

Only patients referred to the Pain Clinic for abdominal trigger point injections for abdominal wall pain will be considered for study recruitment. Following informed consent, patients will complete a baseline questionnaire in the Pain Clinic which gathers basic demographic data, pain scores and functional scores. Patients will be randomized to receive either a TAP injection or a TPI. Because the TAP injection involves a larger area to be anesthetized, a larger volume of medication will be used. Thirty minutes after the injection, a sensory exam will be performed on the patient to determine the level of block. At one week, one month, three months and six months after the injection, a staff member will telephone the patient to assess how they are doing. The call will take approximately 10 minutes and will consist of relaying a pain score as well as daily functioning and sleep questions. Subjects are responsible for all clinical costs associated with the injection. There is no remuneration offered for study participation.

Conditions

Interventions

TypeNameDescription
DRUGBupivacaine 0.25%Bupivacaine is a local anaesthetic drug belonging to the amino amide group.
DRUGTriamcinoloneTriamcinolone is a long-acting synthetic corticosteroid.

Timeline

Start date
2012-01-01
Primary completion
2019-08-18
Completion
2019-08-18
First posted
2013-07-24
Last updated
2020-05-14

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01906944. Inclusion in this directory is not an endorsement.